Table 2.

Multivariate Analysis to Determine Factors Associated With the Occurrence of ≥1 DDI Among the POPVIH65 Cohort (n = 9076)

Characteristics	Odds Ratio [95% CI]	P Value
Age, for 10-y increase	0.87 [0.76–0.98]	.02
No. of ARV drugs	1.35 [1.24–1.47]a	<.0001
No. of comedications (non-ARV)	1.07 [1.06–1.07]a	<.0001
Chronic obstructive pulmonary disease	1.67 [1.36–2.05]	<.0001
Antiretroviral therapy
2 NRTIs + 1 NNRTI (n = 2624)	1.00	—
2 NRTIs + raltegravir or dolutegravir (n = 1512)	0.02 [0.005–0.05]	<.0001
2 NRTIs + 1 boosted third agentb (n = 1271)	4.12 [3.34–5.10]	<.0001
Alternative ARV therapy (n = 1485)	3.58 [2.94–4.37]	<.0001
Inconsistent therapy (n = 2184)	2.41 [1.88–3.09]	<.0001

Abbreviations: ARV, antiretroviral; NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.

^aOdds ratio corresponds to 1-unit increase.

^bProtease inhibitors or elvitegravir.